uPA-Silica-Particles (SP-uPA): A novel analytical system to investigate uPA-uPAR interaction and to test synthetic uPAR antagonists as potential cancer therapeutics

Biological Chemistry

Volumn 383, Issue 1, 2002, Pages 207-216

  Guthaus, Elke ^a   Bürgle, Marcus ^a   Schmiedeberg, Niko ^a   Hocke, Stefan ^a   Eickler, Alexandra ^a   Kramer, Michael D ^a   Sweep, C G J Fred ^a   Magdolen, Viktor ^a   Kessler, Horst ^a   Schmitt, Manfred ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

CD87; Silica particle; Therapeutics; Urokinase; Urokinase receptor

Indexed keywords

CYCLOPEPTIDE; DYE; IMMUNOGLOBULIN G; LIGAND; MONOCLONAL ANTIBODY; PLASMINOGEN ACTIVATOR INHIBITOR; RECOMBINANT PROTEIN; SILICON DIOXIDE; UROKINASE; UROKINASE RECEPTOR; ANTINEOPLASTIC AGENT; CELL SURFACE RECEPTOR; PLASMINOGEN ACTIVATOR, UROKINASE RECEPTORS;

ANALYTICAL EQUIPMENT; ARTICLE; BINDING COMPETITION; CANCER INVASION; CELL ADHESION; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURFACE; CONTROLLED STUDY; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; METASTASIS; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; RECEPTOR BINDING; CELL CULTURE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; IMMUNOASSAY; IMMUNOLOGY; METABOLISM; NEWBORN; PROTEIN BINDING; SOLUBILITY; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FLOW CYTOMETRY; HUMANS; IMMUNOASSAY; INFANT, NEWBORN; MOLECULAR STRUCTURE; PARTICLE SIZE; PEPTIDES, CYCLIC; PROTEIN BINDING; RECEPTORS, CELL SURFACE; SILICON DIOXIDE; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED; URINARY PLASMINOGEN ACTIVATOR;

EID: 0036005974     PISSN: 14316730     EISSN: None     Source Type: Journal    
DOI: 10.1515/BC.2002.021     Document Type: Article

References (48)

1. The urokinase-type plasminogen activator system in cancer metastasis: A review
2. The receptor-binding sequence of urokinase. A biological function for the growth-factor module of proteases
3. Inhibition of the interaction of urokinase-type plasminogen activator (uPA) with its receptor (uPAR) by synthetic peptides
4. Simultaneous quantitation of 15 cytokines using a multiplexed flow cytometric assay
5. Flow cytometric analysis of the urokinase receptor (uPA-R) on tumor cells by fluorescent uPA-ligands or monoclonal antibody #3936
6. Prevention of metastasis by inhibition of the urokinase receptor
7. Complexes between urokinase-type plasminogen activator and its receptor in blood as determined by enzyme-linked immunosorbent assay
8. Urokinase-plasminogen activator, a marker for aggressive breast cancer
9. Differential binding of urokinase and peptide antagonists to the urokinase receptor: Evidence from characterization of the receptor in four primate species
10. Inhibition of prostate cancer neovascularization and growth by urokinase-plasminogen activator receptor blockade
11. High-affinity urokinase receptor antagonists identified with bacteriophage peptide display
12. Quantitative assessment of interaction of urokinase-type plasminogen activator and its receptor (CD87) by use of a solid-phase uPA-ligand binding assay
13. Solution structure of the aminoterminal fragment of urokinase-type plasminogen activator
14. 15N relaxation studies of the amino-terminal fragment of urokinase-type plasminogen activator
15. Inhibition of establishment of primary and micrometastatic tumours by a urokinase plasminogen activator receptor antagonist
16. The urokinase-type plasminogen activator (uPA) antigen is related to early relapse in breast cancer
17. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1
18. Multiplexed fluorescent bead-based immunoassays for quantitation of human cytokines in serum and culture supernatants
19. Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (pro-uPA)
20. Saturation of tumor cell surface receptors for urokinase-type plasminogen activator by amino-terminal fragment and subsequent effect on reconstituted basement membranes invasion
21. A bifunctional hybrid molecule of the amino-terminal fragment urokinase and domain II of bikunin
22. New ELISA for quantitation of human urokinase receptor (CD87) in cancer
23. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87)
24. Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice
25. Ligand binding regions in the receptor for urokinase-type plasminogen activator
26. Different mechanisms are involved in the antibody mediated inhibition of ligand binding to the urokinase receptor: A study based on biosensor technology
27. High level synthesis of recombinant soluble urokinase receptor (CD87) by ovarian cancer cells reduces intraperitoneal tumor growth and spread in nude mice
28. Expression of the human urokinase-type plasminogen activator receptor in E. coli and Chinese hamster ovary cells: Purification of the recombinant proteins and generation of polyclonal antibodies in chicken
29. Systematic mutational analysis of the receptor-binding region of the human urokinase-type plasminogen activator
30. Cyclo 19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87)
31. The urokinase plasminogen activator receptor (uPAR) as a target for the diagnosis and therapy of cancer
32. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice
33. r receptor protein for urokinase-type plasminogen activator. Identification in human tumor cell lines and partial purification
34. Protein structure and membrane anchorage of the cellular receptor for urokinase-type plasminogen activator
35. Peptide-derived antagonists of the urokinase receptor. Affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation
36. The role of the plasminogen activation system in angiogenesis and metastasis
37. A competitive chromogenic assay to study the functional interaction of urokinase-type plasminogen activator with its receptor
38. Multifunctional potential of plasminogen activation system in tumor invasion and metastasis
39. Design and biological activity of new high-affinity ligands for the urokinase-type plasminogen activator receptor (CD87)
40. Fluorescent probes as tools to assess the receptor for the urokinase-type plasminogen activator on tumor cells
41. Tumor-associated proteases
42. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: Prognostic relevance and target for therapy
43. The urokinase plasminogen activator system as a novel target for tumour therapy
44. Immunolocalization of urokinase-type plasminogen activator (uPA) in adenomas and carcinomas of the human colon
45. A bead-based method for multiplexed identification and quantitation of DNA sequences using flow cytometry
46. Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes
47. Urokinase receptor antagonists: Discovery and application to in vivo models of tumor growth
48. Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice